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ABSTRACT
Objective: To compare boric acid as an effective treatment for VVC compared to 
fluconazole. We also studied the efficiency of these drugs in preventing recurrence 
of VVC. 
Design:  A cross sectional, randomized, double-blind study.
Settings: Gynaecology clinic of Imam Reza hospital, Tehran - Iran
Subjects: Women with signs and symptoms related to Vulvo Vaginal Candidiasis. 
Results: Seventy five patients out of total 150 patients with signs and symptoms related 
to Vulvo Vaginal Candidiasis were treated with boric acid powder every night for a week 
and the remaining 75 patients received Fluconazole. The cure rate in first group was 
46.7% but the cure rate in second group was 37.3%. The difference was not statistically 
significant (P>0.3). Difference between the efficacy of the two drugs was not significant 
either (P=0.47). The recurrence rate among patients in first group was 35% while it 
was 32% in second group. Their difference was not statistically significant (P=0.54).
Conclusion: According to our findings, treatment of vaginal candidiasis with boric acid 
is as effective as fluconazole. The availability of boric acid and its relatively low cost 
suggests it as a safe and effective drug for treatment of candidiasis. 
INTRODUCTION
Vulvo-Vaginal Candidiasis (VVC) is a frequent 
cause of mycoses of women caused by Candida (C.) 
species. C. albicans is the main causative agent (87.6%) 
followed by C. glabrata (6.2%) and C. krusei (2.2%) 
(1). C. albicans and C. glabrata are often involved in 
recurrent vulvovaginal candidiasis (2). 
	 Different	azol	compounds	are	used	for	treating	
Candidiasis (1,3-6). Non-azole compounds are also 
used for mycotic vaginitis.
 Ringdahl (11) proved that C. albicans also 
responds	to	azole	antifungal	agents	like	fluconazole.	
According	to	him	individuals	suffering	from	vaginitis	
due to Candida are bothered by recurrent vaginal 
yeast infections or experience failure of conventional 
therapies. He advised maintenance therapy to be 
started immediately after treatment of the acute 
episode and to be continued for six months (7,8). 
 Sojakova et al concluded that antifungal agents 
used to treat vaginitis may be contributing to the drug 
resistance problem by promoting cross-resistance to 
a range of clinically used antifungals (1).
The use of boric acid as a home remedy has long 
been in existence. Boric acid or boracic [B(OH)3] is 
a weak acid, and acidic properties of boric acid may 
lead to disruption of the fungal cell wall though Ray 
et al believe	that	the	effect	of	boric	acid	is	not	specific	
to its acidic properties (9). Clinical reports indicate 
success in treating vaginal candidiasis, especially 
non-albicans vaginitis with boric acid (10). 
 Vulvovaginal candidiasis is considered recurrent 
when	 at	 least	 four	 specific	 episodes	 occur	 in	 one	
year or at least three episodes unrelated to antibiotic 
therapy occur within one year (11). 
	 Recurrent	vulvovaginal	candidiasis	affects	five	
percent of women of child-bearing age. The most 
common organism is Candidia albicans, but an 
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increasing number of infections are caused by non-
albicans species (7). During any treatment regimen, it 
is crucial that patients are carefully examined clinically 
and microscopically via culture-proven absence of 
Candida (12). 




of VVC as well. 
MATERIALS AND METHODS
This randomised double-blind study was carried out 
in gynecology clinic of Imam Reza hospital, Tehran 
- Iran. All patients with symptoms like pruritis, 
irritation, burning, discharge, splash dysuria and 
signs	of	inflammation	including	erythema,	edema,	
excoriation,	fissures	were	examined	in	the	clinic.	
Written informed consent was obtained from every 
patient after they were informed about the protocol 
though they were blind regarding the drug they 
received.
 Ethical committee number was obtained from 
our Institution Ethics Committee.
Case Selection: Microscopic examination and culturing 
of patients' secretions were performed to identify the 
etiologic agent. All patients with active acute Candida 
vaginitis were enrolled in the study.
 Some patients were excluded from the study 
on the basis of our exclusion criteria like pregnancy, 
mixed infection and treatment with antifungal agents 
within last four months. 
 At last, study was carried out with 150 patients. 
They were randomly grouped into two categories: 
group I with 75 patients received hand–made capsules 
filled	with	600	mg	boric	acid	powder	every	night	for	
a week and 75 patients included in group II received 
1 capsule of 150 mg Fluconazole (Pars Darou co.). 
All the patients were prohibited from any other 
medication during the treatment and follow up. 
All patients and the statistician were totally blind 
regarding the type of medication employed.
Patients' assessment and follow up: Patients were 
assessed after two weeks of treatment. In every visit 
pelvic examination was carried out. Collected vaginal 
swabs were examined by direct microscopy using 
10% KOH and cultured in Saboraud’s dextrose agar 
to identify Candida species, if present. 
 Patients who had negative laboratory tests were 
followed up and were again assessed after six weeks 
of treatment. Patients who had positive laboratory 
tests especially positive culture test were considered 
as drug resistant and were excluded from the study. 
They were treated with alternate medications. 
 Patients were followed up to six weeks for 
recurrence of the disease and in order to evaluate the 
efficacy	of	these	drugs	in	prevention	of	recurrence.
Data were analyzed using SPSS- software.
RESULTS 
One	 hundred	 and	 fifty	 patients	with	 active	 acute	
Candida vaginitis were included in the study. Their 
age ranged from 18 to 45 years. Their mean age was 30 
± 5.88 years. The frequency of the signs and symptoms 
before and after treatment (Table 1). 
Table 1
The frequency of the symptoms in two groups before & after treatment



















Pruritis 67 (90) 58 (77.4) 125 (83) 15 (20) 17 (22) 34 (21) 7 (14.6) 7 (15.5) 14 (15)
Burning 30 (40) 33 (44) 63 (42) 7 (9.3) 8 (10.6) 15 (11) 3 (6.6) 4 (8.3) 7 (7.5)
Splash Dysuria 15 (20) 13 (17.3) 28 (18.6) 3 (4) 4 (5.3) 7 (4.5) 1 (2.2) 7 (4) 3 (3.1)
Secretions 45 (60) 50 (66) 95 (63) 15 (20) 12 (16) 27 (18) 5 (10.4) 7 (15.5) 12 (13)
Inflammation 68 (90) 75 (100) 143 (95) 154 (20) 17  22) 37 (16) 7 (14.6) 7 (15.5) 14 (15.5)
Symptoms & signs 
before treatment
Symptoms & signs 2 
weeks after treatment
Symptoms & signs 6 
weeks after treatment
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As is clear from Table-1, inflammation is the 
commonest	 sign	 in	 patients	 suffering	 from	 vulvo	
vaginal candidiasis followed by pruritis, secretion, 
burning sensation and splash dysuria (before 
treatment).
	 Two	weeks	after	 treatment	 inflammation	and	
pruritis are still the predominant signs and symptoms 
in both groups while discharge is also as common as 
the	other	two	signs	amongst	patients	of	first	group	
followed by burning sensation and splash dysuria 
in both the groups.
	 To	find	out	the	relationship	between	the	kind	of	
group variables and type of illness we used Chi-square 
test.	We	found	no	significant	difference	between	group	
I and II in all types of signs and symptoms (pruritis, 
burning sensation, secretions, splash dysuria and 
inflammation)	(P>0.05).
 We studied the behaviour of two variables (time 
versus kind of signs) in two groups independently. 
Applying Pearson's Chi-Square test, we found 
no	 significant	 difference	 between	 time	 of	 illness	
regarding all types of signs and symptoms in group I 
(P>0.05),	indicating	the	time	of	illness	is	independent	
of signs and symptoms of illness.
 Figure I shows the number of signs and 
symptoms present in group I based on time of study 
(that is, before and after treatment) versus signs of 
illness. 
Figure 1






2 weeks after treatment
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Figure 2
Number of signs present in group II based on time of study (i.e. before and after treatment) versus kind of signs of 
illness
As	 in	 the	 present	 study	 two	 categorical	 fields	 are	
specified	and	they	have	only	two	values,	McNemar's	
test	 is	 applied	 to	 find	 out	 whether	 combinations	
of values between two dichotomous variables are 
equally likely or not. We considered six variables 
in two groups of study cases. In each group, we 
compared patients’ signs and symptoms before 
treatment and presence of their clinical signs and 
symptoms after two weeks and recurrence after six 
weeks	of	treatment	with	boric	acid	and	fluconazol	
(Table 1).
 McNemar's test was run to show if there is 
significant	difference	regarding	the	presence	of	the	
above mentioned variables.  Based on the results 
obtained,	it	can	be	concluded	that	there	is	significant	
difference between presence of the concerned 
variables “before treatment” and “after two weeks 
treatment with boric acid” (P<0.05).
 McNemar's test was also run to show if there 
is	 significant	 difference	 regarding	 the	 presence	 of	




presence of clinical signs and symptoms (P< 0.05). 
 Out of 75 patients treated with boric acid 46.7% 
patients were cured of clinical signs two weeks after 
treatment. Their samples cultured after two weeks 
were also negative. While 37.3% patient treated with 
Fluconazole had no clinical signs and symptoms after 
two weeks and the culture of their samples were 
negative	 after	 this	 period	 of	 treatment.	Difference	
between	the	efficacy	of	two	drugs	was	not	significant	
(P=0.47).
 The cure rate is calculated on the basis of number 
of negative cultures of patients' samples after two 
weeks of treatment and lack of any clinical sign and 
symptom.
	 The	 cure	 rate	 in	 first	 group	 after	 two	weeks	
of treatment was 46.7% but the cure rate in second 
group after two weeks of treatment was 37.3%. The 
difference	 was	 not	 statistically	 significant	 (P>0.3)	
(Table 2). 
 Six weeks after treatment with boric acid 14% 
patients had symptoms related to vulvo vaginal 
candidiasis. Twenty seven percent patients were 
culture positive, while 15.5% patient treated with 
fluconazole	had	symptoms	six	weeks	after	treatment.	
Thirty seven percent patients were also culture 
positive (Table 2). 
time
before treatment
2 weeks after treatment
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Table 2
Recurrence rate in both the study groups
             Grouping Group I  
    (%)
Group II  
      (%)
Outcome of  
Treatment
Presence of symptoms 10.5 (14) 11.62 (15.5)
Positive culture of patients samples 20.25 (27) 27.75 (37)
Recurrence rate 26.25  (35) 24 (32)
 The recurrence rate based on microscopic 
examination of patients' samples after six weeks of 
















(P<0.05) (Figure 1).             
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Figure 4
The "level of significance" of signs between two groups in all three stages
DISCUSSION
According to Ringdahl more than 50 percent of 
women older than 25 years develop vulvovaginal 
candidiasis at some time and fewer than 5 percent of 
these women experience recurrences (11).
 In our study all patients had signs and symptoms 
related to candidiasis. The clinical diagnosis was 
confirmed	by	laboratory	findings.	
 As is conventional (9,13), we also treated a 
group of our patients with an azole compound i.e. 
fluconazole.	The	problem	may	persist	despite	topical	
or oral use of azole antifungal drugs. As conventional 
treatments are not always successful and may lead 
to drug resistance and/or recurrences (13,14), we 
compared	the	efficacy	of	fluconazole	with	a	cheaper	
yet safer drug, that is, boric acid. We also studied the 
efficiency	of	these	drugs	in	preventing	recurrence	of	
VVC as well. 
 Donders et al believe that for acute Candida 
vaginitis any oral or local anti-fungal therapy can 
be used but for women with recurrent vulvo-vaginal 
candidiasis	(RVC)	simple	approaches	are	insufficient	
and instead, RVC should be managed as any 
other chronic disease and long-term, prophylactic, 
suppressive antifungal treatment is required (12).
	 In	the	present	study	we	compared	the	efficacy	
of boric acid as an alternative treatment for VVC. It 
can	be	a	substitute	 for	azol	drugs	as	 it	 is	effective	
against both C. albicans and C. glabrata compared with 
fluconazole,	which	is	effective	against	C. albicans only 
(9).
 In this study patients received hand made 
capsules of boric acid containing 600 mg boric acid 
powder every night for a week and 46.7% patients 
were cured of clinical signs two weeks after treatment 
whilst the mycologic cure rate varies from 40 to 100% 
(8). The lower cure rate  in the present study compared 
to	>90%	mycological	cure	achieved	by	vaginal	use	of	
600 mg boric acid daily for 14 days (15) may be due 
to our shorter duration of treatment or the species 
involved.	We	observed	no	boric	acid	side	effects.	
In conclusion, boric acid therapy of vaginal candidiasis 
has also been found to be safe and in our study we 
did	not	observe	any	side	effect.	
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